Health Secretary RFK Jr.'s annual financial disclosure is significantly overdue, a delay his team attributes to the painstaking process of ensuring his personal earnings from a vaccine-related lawsuit against Merck have fully matured now that he regulates the pharmaceutical industry. The report, expected to detail substantial income from his long-standing legal battle, has missed its filing deadline with no new date set.
"Mr. Kennedy believes in full transparency," stated a spokesperson, who requested anonymity while diligently updating their LinkedIn profile. "But it would be financially irresponsible to file before his various settlements, particularly the one with Merck, have had the chance to fully appreciate. Why rush to show a partial picture when a richer, more accurate one, reflecting his true market value, is just around the corner? This isn't a conflict of interest; it's simply optimal asset management achieved through strategic federal positioning."
Dr. Vance Thorne, Director of the newly rebranded Institute for Ethical Monetization of Public Service, praised the approach as a groundbreaking innovation. "This is not merely public service; it's a masterclass in value extraction," Dr. Thorne explained during a webinar titled 'Your Government Role: A Guide to Personal Wealth Amplification.' "By stepping into a regulatory role, Mr. Kennedy has dramatically increased the negotiating power of his personal legal claims. Any earlier disclosure would have severely undervalued his unique ability to simultaneously litigate against and oversee pharmaceutical companies. We're witnessing synergistic governance at its finest—a true win-win for Mr. Kennedy."
The strategic delay has reportedly caused a surge of interest among other wealthy presidential appointees, with several high-net-worth individuals now consulting ethics lawyers on how best to "optimize their regulatory impact" before publicly disclosing their own portfolios. One senior aide, speaking off the record from a yacht docked somewhere offshore, noted, "It's not about making a quick buck; it's about making *all* the bucks. And if you have to sit on a disclosure for a few months while you gently persuade a few major corporations to settle up, well, that's just good business. Plus, it gives us more time to find a private island."
The White House has remained silent on the delay, implicitly signaling tacit approval of the innovative new standard for public officials. Legal scholars are already predicting a wave of new appointments specifically designed to maximize personal gain from previously adversarial industries, hailing it as the most efficient form of government-corporate partnership yet. "Why fight them when you can just join them and then bill them?" mused one cynical Beltway insider, lighting a cigar with a crisp hundred-dollar bill.
Kennedy’s team assured the public that his financial transparency was paramount, secondary only to ensuring his bank accounts fully reflected the unprecedented value of his unique position as a federal regulator.
